Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
-Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus
DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
Table: IMU-838 Shows Acceleration of Time to Clinical Improvement
High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population:
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients
[6], as compared to placebo (FAS).
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 4.8 days in IMU-838 treated elderly patients (65 years or older), as compared to placebo (FAS).